(+)-butaclamol
Sign in to saveButaclamol (AY-23,028) is a type of antipsychotic which was never marketed. Sold as the hydrochloride salt for use in research, the compound acts as a dopamine receptor antagonist. ==Discussion== pKa = 7.15 (uncorrected for ionic strength)
Research
546 papers- Protective Effects of (-)-Butaclamol Against Gentamicin-Induced Ototoxicity: In Vivo and In Vitro Approaches.International journal of molecular sciences · 2025
- Butaclamol hydrochloride in newly admitted schizophrenics.Psychopharmacology communications · 1975
- Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.International pharmacopsychiatry · 1978
- Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.Journal of medicinal chemistry · 1979
- [Effect of butaclamol enantiomers on hypothalamic tyrosine hydroxylase in the rat brain].Biulleten' eksperimental'noi biologii i meditsiny · 1984
via PubMed
~2 min read
Encyclopedic overview
4 sectionsContents
- Discussion
- Synthesis
- See also
- References
Butaclamol (AY-23,028) is a type of antipsychotic which was never marketed. Sold as the hydrochloride salt for use in research, the compound acts as a dopamine receptor antagonist. ==Discussion== pKa = 7.15 (uncorrected for ionic strength)
McN-4171 is an analog of butaclamol. McN-4612-Y is also described in the attached article. This is similar to McN 4612-z except it is the opposite optical antipode. It is therefore supposedly an antipsychotic.
Excerpted from Wikipedia’s “(+)-butaclamol” article, available under the CC BY-SA 4.0 licence.